Navigation Links
Erbitux Works Well for Two-Thirds of Colon Cancer Patients
Date:6/1/2008

e combination therapy as opposed to chemotherapy alone.

Since that time, the biology of KRAS has become better understood, and other studies have shown the value of the combination treatment as a third-line treatment. "Those with the KRAS mutation were resistant to cetuximab in third-line treatment," van Cutsem said.

Results were even clearer in the current set of findings, culled from tumor samples from 587 patients. Those with normal KRAS genes had a 32 percent reduced risk of developing a recurrence during the study period, compared with a 15 percent reduction for all patients.

"At one year, progression-free survival was 25 percent for those [taking chemotherapy alone] and 43 percent in the combination group," van Cutsem said. "In KRAS-mutant patients, there was no difference."

Also, 59.3 percent of normal gene patients responded to the combination treatment (tumors shrank by more than half), while only 43.2 percent of those on chemo alone responded. There were no differences in response rates among those with the mutation.

The study looked only at first-line treatment in patients with colorectal cancer which had already spread to other parts of their body. Side effects were "manageable," van Cutsem said.

"This is an exciting area of targeted agents," said Dr. Julie Gralow, moderator of the news conference at which the findings were presented and director of breast oncology at the University of Washington and Fred Hutchinson Cancer Center in Seattle. "The question is, how are we going to able to afford these drugs in these patients? It's exciting that KRAS seems to predict who will benefit. The wild-type is two-thirds of patients who will benefit. We don't need to give this drug to the other third now."

More information

The American Cancer Society has more on colon and rectum cancer.
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
2. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
3. Erbitux Plus Chemo Improves Lung Cancer Outcomes
4. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
5. Taxol bristle ball: a wrench in the works for cancer
6. Cancer control in Europe works; now it is time to extend it to poorer countries
7. SecureWorks Ranked 6th in Deloittes Technology Fast 50 Program for Georgia
8. AK Steel Reaches VEBA Health Care Settlement With Middletown Works Retirees
9. IOM workshop on less confusing drug labeling, Oct. 12
10. CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0
11. Crittenton Hospital Medical Center to Participate in United Physicians myWorkspace(R) Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... As obesity rates sky rocket in the United ... during childbirth comes as no shock. Forceps are surgical equipment ... she is unable to do so herself and although they ... rates of complication for both the mother and the baby. ... and child, forceps births add to the pressure of healthcare ...
(Date:6/18/2013)... Senior drug regulatory officials from mainland China ... discuss—for the first time in the U.S.—the need for more ... regulatory process in a timely manner. Representatives from the Taiwan ... best practices and processes in drug review during the ... the DIA 2013 49th Annual Meeting . ...
(Date:6/18/2013)... CA (PRWEB) June 18, 2013 Seven-year-old ... to recovery from autism. He receives 40 hours a ... and school shadowing) from the Center for Autism and ... CARD since August, 2008, and has experienced remarkable progress, ... commenting about his environment. Riley’s personal journey through autism ...
(Date:6/18/2013)... Researchers have discovered and mapped the signaling network between ... broken, could cut off cancer cell growth at its ... The University of Texas MD Anderson Cancer Center reported ... well-known cancer drug target, and MCM7, a protein vital ... June issue of Cancer Cell . , "MCM7 ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Two months ago, ... going into surgery for a second session of a silicone ... Miami-Dade County. The treatment was allegedly performed by a mystery ... the board. According to Dr. Bernabe Vazquez of ... receiving such treatments from doctor’s who are not board certified ...
Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3
... DIEGO, Nov. 12 Halozyme Therapeutics,Inc. (Nasdaq: HALO ... the extracellular matrix, today announced,that it has been selected ... ), effective Monday, November 19. Launched in 1993, ... in May and November and serves as the basis ...
... Inc., (Nasdaq:,QMED) today announced that it has retained ... alternatives. Lazard Middle Market is the middle,market financial ... with Lazard Middle Market Healthcare Services group will ... of Directors. Additionally, Bruce Wesson, QMed,s Chairman, ...
... Ph.D. program in Nurse Education at Mercer, ... R. Timothy Stack and Mercer University President William,D. ... Healthcare,Chair in Nursing that will benefit Georgia Baptist ... by a $2.85 million grant to the,Center for ...
... training to manage the condition , , MONDAY, Nov. 12 ... illness rather than treating it, but a new study ... difference for people with one tough-to-treat condition: fibromyalgia. , ... moderately for four months reported feeling better in a ...
... The Foundation for the Scientific Study of Sexuality (FSSS) ... Rutgers College of Nursing emerita faculty member Beverly Whipple for ... anniversary meeting of the Society for the Scientific Study of ... Vern L. Bullough Award is given by FSSS for the ...
... November 18 at 9 ... AM ET/PT on Discovery Health -, NEW YORK, ... -- one of the most pressing health crises facing,humanity today. Currently, ... number that is expected to explode to 380,million within 20 years. ...
Cached Medicine News:Health News:Halozyme Therapeutics Added to Nasdaq Biotech Index 2Health News:Piedmont Healthcare Funds Nursing Chair at Mercer University 2Health News:Piedmont Healthcare Funds Nursing Chair at Mercer University 3Health News:Exercise Eases Fibromyalgia Symptoms: Study 2Health News:Exercise Eases Fibromyalgia Symptoms: Study 3Health News:Rutgers College of Nursing emerita professor Beverly Whipple receives FSSS book award 2Health News:Discovery Health Travels the World to Present the Groundbreaking Documentary - Diabetes: A Global Epidemic 2Health News:Discovery Health Travels the World to Present the Groundbreaking Documentary - Diabetes: A Global Epidemic 3Health News:Discovery Health Travels the World to Present the Groundbreaking Documentary - Diabetes: A Global Epidemic 4
(Date:6/18/2013)... 2013  Recent regulatory and budget challenges have made ... at large pharmaceutical companies to effectively educate doctors and ... of their new products. With the pressure to reduce ... that these "Med Ed" groups find practical, ... address the changes that are transforming the Medical Education ...
(Date:6/18/2013)... Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ... of injectable drug delivery systems, today announced the launch ... The new site includes additional products, videos, features, blogs ... regular basis. Mr. Alan Shortall , ... leader for injectable drug delivery systems, we have created ...
(Date:6/18/2013)... 2013  Specialty Coating Systems is pleased ... coating technologies: SCS microRESIST™ Antimicrobial Parylene Technology. ... with antimicrobial properties to effectively eliminate harmful ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... continue to pose a challenge to hospitals ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2Unilife Launches New Corporate Website 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... 24, 2011 Omnicell, Inc . (Nasdaq: ... supply chain management solutions to healthcare facilities, today announced ... GS1 standards. GS1 is an international association ... and solutions to improve the efficiency and visibility of ...
... Calif., March 24, 2011 Molecular Devices, Inc. and ... drug discovery tools and solutions, have signed an agreement ... ion channel and GPCR cell lines on a non-exclusive ... will sell ChanTest,s ion channel and GPCR cell lines ...
Cached Medicine Technology:Leading Hospitals Committed to Healthcare's Adoption of GS1 Standards Use Omnicell Solutions for Supply Chain Management 2Leading Hospitals Committed to Healthcare's Adoption of GS1 Standards Use Omnicell Solutions for Supply Chain Management 3Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement 2Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement 3
PoleStar N-10 is a compact MRI unit that does not require a specially constructed surgery suite. The magnetic field is confined to the volume between the magnet poles and it's immediate neighborhood....
... Adhesive (Bioglue) is a two-component surgical ... albumin (BSA) and glutaraldehyde. The BSA ... bovine spongiform encephalopathy (BSE) free countries ... inactivates viruses. The solutions are dispensed ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: